Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients.
Objective: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have well-documented effects in reducing hospitalization or cardiovascular mortality, while the association of SGLT2 inhibitor dapagliflozin (DAPA) and the risk of acute kidney injury (AKI) in acute myocardial infarction (AMI) patients has...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 80; no. 4; pp. 613 - 621 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
Apr2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |